Omnicell (OMCL)
(Delayed Data from NSDQ)
$44.48 USD
-0.78 (-1.72%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $44.31 -0.17 (-0.38%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.48 USD
-0.78 (-1.72%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $44.31 -0.17 (-0.38%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
Phreesia (PHR) Soars 5.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Phreesia (PHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Omnicell (OMCL) Down 5.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJT
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
CHNG vs. OMCL: Which Stock Is the Better Value Option?
by Zacks Equity Research
CHNG vs. OMCL: Which Stock Is the Better Value Option?
Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLYG
Should Vanguard S&P SmallCap 600 Growth ETF (VIOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOG
Omnicell (OMCL) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Robust performance by the Product and Service segments is driving Omnicell's (OMCL) fourth-quarter top line.
Omnicell (OMCL) Lags Q4 Earnings Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of -3.16% and 0.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CPSI vs. OMCL: Which Stock Is the Better Value Option?
by Zacks Equity Research
CPSI vs. OMCL: Which Stock Is the Better Value Option?
Omnicell (OMCL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLY
Should iShares Core S&P SmallCap ETF (IJR) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJR
Ford Motor and IRobot have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Ford Motor and IRobot have been highlighted as Zacks Bull and Bear of the Day
Omicron Hits Elective MedTechs, 3 Subsectors Likely to Thrive
by Urmimala Biswas
Here we discuss three major subsectors of MedTech and three constituent stocks, OPCH, GMED and OMCL for which the change in the scenario has opened up enormous growth prospects.
Omnicell (OMCL) to Expand EnlivenHealth Division With New Buyout
by Zacks Equity Research
Omnicell's (OMCL) $82-million buyout of MarkeTouch Media is likely to expand its Advanced Services portfolio.
Here's Why You Should Add Omnicell (OMCL) Stock for Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) on strength in medication management and adherence automation solutions.
Is Dynavax Technologies (DVAX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Dynavax Technologies (DVAX) and Omnicell (OMCL) have performed compared to their sector so far this year.
Omnicell (OMCL) Closes ReCept Holdings Acquisition Deal
by Zacks Equity Research
Omnicell's (OMCL) completed buyout of the renowned specialty pharmacy management services provider is likely to bolster its Advanced Services offering.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJT
3 Reasons Why Growth Investors Shouldn't Overlook Omnicell (OMCL)
by Zacks Equity Research
Omnicell (OMCL) could produce exceptional returns because of its solid growth attributes.
CERN vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CERN vs. OMCL: Which Stock Is the Better Value Option?
Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLYG
Should Vanguard S&P SmallCap 600 Growth ETF (VIOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOG